RecruitingNot ApplicableNCT06911697

Study on c-Met Targeted PET/CT Imaging in NSCLC

In Vivo Detection of c-Met Activation Status by Specific PET/CT Imaging Based on 18F Labeled Small Molecule TKI


Sponsor

Xilin Sun

Enrollment

88 participants

Start Date

Oct 26, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria8

  • Age range 18-75 years, open to both male and female participants;
  • Normal hepatic/renal function and cardiac function;
  • Expected survival of at least 12 weeks;
  • Good adherence to follow-up;
  • Presence of at least one measurable target lesion according to RECIST 1.1 criteria;
  • Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;
  • Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors;
  • Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.

Exclusion Criteria7

  • Severe abnormalities in liver and renal function and blood counts;
  • Patients planning to conceive;
  • Pregnant or lactating women;
  • Individuals unable to lie flat for thirty minutes;
  • Individuals who refuse to participate in this clinical study;
  • Individuals suffering from claustrophobia or other psychiatric disorders;
  • Other situations deemed unsuitable for trial participation by the researchers.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST18F-TSPF PET/CT

Each subject receives interval imaging of 18F-TSPF PET/CT and 18F-FDG PET/CT, and further follow-up.


Locations(1)

Department of Nuclear Medicine, Fourth Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06911697


Related Trials